Review



bms 986202  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress bms 986202
    TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or <t>TYK2i</t> <t>BMS-986202</t> (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
    Bms 986202, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bms 986202/product/MedChemExpress
    Average 93 stars, based on 3 article reviews
    bms 986202 - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice"

    Article Title: Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice

    Journal: eBioMedicine

    doi: 10.1016/j.ebiom.2025.105734

    TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or TYK2i BMS-986202 (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
    Figure Legend Snippet: TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or TYK2i BMS-986202 (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.

    Techniques Used: Inhibition



    Similar Products

    bms 986202  (MedChemExpress)
    93
    MedChemExpress bms 986202
    TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or <t>TYK2i</t> <t>BMS-986202</t> (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
    Bms 986202, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bms 986202/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    bms 986202 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    compounds bms- 986202  (Bristol Myers)
    90
    Bristol Myers compounds bms- 986202
    TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or <t>TYK2i</t> <t>BMS-986202</t> (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
    Compounds Bms 986202, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/compounds bms- 986202/product/Bristol Myers
    Average 90 stars, based on 1 article reviews
    compounds bms- 986202 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tyk2 inhibitor bms- 986202  (Bristol Myers)
    90
    Bristol Myers tyk2 inhibitor bms- 986202
    TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or <t>TYK2i</t> <t>BMS-986202</t> (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
    Tyk2 Inhibitor Bms 986202, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tyk2 inhibitor bms- 986202/product/Bristol Myers
    Average 90 stars, based on 1 article reviews
    tyk2 inhibitor bms- 986202 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bms-986202  (Bristol Myers)
    90
    Bristol Myers bms-986202
    TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or <t>TYK2i</t> <t>BMS-986202</t> (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
    Bms 986202, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bms-986202/product/Bristol Myers
    Average 90 stars, based on 1 article reviews
    bms-986202 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bms-986202 (32)  (Bristol Myers)
    90
    Bristol Myers bms-986202 (32)
    TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or <t>TYK2i</t> <t>BMS-986202</t> (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
    Bms 986202 (32), supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bms-986202 (32)/product/Bristol Myers
    Average 90 stars, based on 1 article reviews
    bms-986202 (32) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tyk2 inhibitor bms-986202  (Bristol Myers)
    90
    Bristol Myers tyk2 inhibitor bms-986202
    TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or <t>TYK2i</t> <t>BMS-986202</t> (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
    Tyk2 Inhibitor Bms 986202, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tyk2 inhibitor bms-986202/product/Bristol Myers
    Average 90 stars, based on 1 article reviews
    tyk2 inhibitor bms-986202 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or TYK2i BMS-986202 (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.

    Journal: eBioMedicine

    Article Title: Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice

    doi: 10.1016/j.ebiom.2025.105734

    Figure Lengend Snippet: TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or TYK2i BMS-986202 (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.

    Article Snippet: Cells were treated with the TYK2i BMS-986165 (MedChemExpress, catalogue #HY-117287) or BMS-986202 (a kind gift from Bristol Myers Squibb) at different concentrations ranging from 0.0003 to 3 μM and with different proinflammatory cytokines alone or in combination: IFNα (2000 U/mL, PeproTech, catalogue #300-02AA-1MG), IL-1β (50 U/mL, R&D Systems, catalogue #201-LB-005), and TNFα (1000 U/mL, PeproTech, catalogue #300-01A-50UG).

    Techniques: Inhibition